Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery

Journal of Neuropathology and Experimental Neurology

Volumn 66, Issue 4, 2007, Pages 272-283

  De La Monte, Suzanne M ^a   Jhaveri, Ami ^a   Maron, Bradley A ^a   Wands, Jack R ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Experimental model of neurodegeneration; In vivo gene delivery; Nitric oxide synthase

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINE ACETYLTRANSFERASE; COMPLEMENTARY DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; HU PROTEIN; LUCIFERASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMID DNA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; GENE DELIVERY SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; LONG EVANS RAT; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; BRAIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; HUMANS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, LONG-EVANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAU PROTEINS; TIME FACTORS;

EID: 34147179927     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/nen.0b013e318040cfa2     Document Type: Article

References (84)

1. Schmidt H, Walter U. NO at work. Cell 1994;78:919-25
2. 2+/calmodulin dependent nitric oxide synthase and a soluble guanylyl cyclase in vertebrate photoreceptor cells. EMBO J 1994;13:3312-20
3. Lincoln J, Hoyle CHV, Burnstock G. Nitric Oxide in Health and Disease, 1st ed. Cambridge, UK: Cambridge University Press, 1997
4. 2+/calmodulin-dependent cytochrome c reductase activity of brain nitric oxide synthase. J Biol Chem 1992;267:11374-78
5. Boje K, Arora P. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 1992;587:250-56
6. Koprowski H, Zheng Y, Heber-Katz E, et al. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci USA 1993;90:3024-27
7. Merrill J, Ignarro L, Sherman M, et al. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 1993;151:2132-41
8. Ghafourifar P, Richter C. Nitric oxide synthase activity in mitochondria. FEBS Lett 1997;418:291-96
9. Ghafourifar P, Schenk U, Klein SD, et al. Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria: evidence for intramitochondrial peroxynitrite formation. J Biol Chem 1999;274:31185-88
10. Giulivi C, Poderoso JJ, Boveris A. Production of nitric oxide by mitochondria. J Biol Chem 1998;273:11038-43
11. Hess D, Patterson S, Smith D, et al. Neuronal growth cone collapse and inhibition of protein fatty acylation by nitric oxide. Nature 1994;366:562-65
12. Mesenge C, Verrecchia C, Allix M, et al. Reduction of the neurological deficit in mice with traumatic brain injury by nitric oxide synthase inhibitors. J Neurotrauma 1996;13:11-16
13. Klatt P, Schmidt K, Uray G, et al. Multiple catalytic functions of brain nitric oxide synthase: Biochemical characterization, cofactor requirement, and the role of Nw-hydroxy-l-arginine as an intermediate. J Biol Chem 1993;268:14781-87
14. Nishikawa T, Kirsch J, Koehler R, et al. Effect of nitric oxide synthase inhibition on cerebral blood flow and injury volume during focal ischemia in cats. Stroke 1993;24:1717-24
15. Satou T, Cummings BJ, Cotman CW, et al. Immunoreactivity for Bcl-2 protein within neurons in the Alzheimer's disease brain increases with disease severity. Brain Res 1995;697:35-43
16. Bredt D, Snyder S. Transient nitric oxide synthase neurons in embryonic cerebral cortical plate, sensory ganglia, and olfactory epithelium. Neuron 1994;13:301-13
17. Dinerman JL, Dawson TM, Schell MJ, et al. Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: Implications for synaptic plasticity. Proc Natl Acad Sci USA 1994;91:4214-18
18. O'Dell TJ, Huang PL, Dawson TM, et al. Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science 1994;265:542-46
19. Esiri M, Morris JE. The Neuropathology of Dementia. Cambridge, UK: Cambridge University Press, 1997
20. Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol 1996;6:493-506
21. de la Monte SM, Sohn YK, Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 1997;152:73-83
22. de la Monte SM, Sohn YK, Ganju N, et al. P53- and CD95-associated apoptosis in neurodegenerative diseases. Lab Invest 1998;78:401-11
23. de la Monte SM, Luong T, Neely TR, et al. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest 2000;80:1323-35
24. Kitamura Y, Shimohama S, Kamoshima W, et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res 1998;780:260-69
25. MacGibbon GA, Lawlor PA, Sirimanne ES, et al. Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. Brain Res 1997;750:223-34
26. Perry G, Nunomura A. Apoptosis and Alzheimer's disease (Letter). Science 1998;282:1268-69
27. Stadelmann C, Bruck W, Bancher C, et al. Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol 1998;57:456-64
28. Su JH, Anderson AJ, Cummings BJ, Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994;5:2529-33
29. Su JH, Deng G, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol 1997;56:86-93
30. Tortosa A, Lopez E, Ferrer I. Bcl-2 and Bax protein expression in Alzheimer's disease. Acta Neuropathol (Berl) 1998;95:407-12
31. de la Monte S, Bloch K. Aberrant expression of the constitutive endothelial nitric oxide synthase gene in Alzheimer's disease. Mol Chem Neuropathol 1997;30:139-59
32. de la Monte SM, Lu BX, Sohn YK, et al. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: Relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging 2000;21:309-19
33. Sohn YK, Ganju N, Bloch KD, et al. Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases. J Neurol Sci 1999;162:133-51
34. Vodovotz Y, Lucia M, Flanders K, et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996;184:1425-33
35. de la Monte SM, Chiche J, von dem Bussche A, et al. Nitric oxide synthase-3 overexpression causes apoptosis and impairs neuronal mitochondrial function: Relevance to Alzheimer's-type neurodegeneration. Lab Invest 2003;83:287-98
36. Xu J, Yeon JE, Chang H, et al. Ethanol impairs insulin-stimulated neuronal survival in the developing brain: Role of PTEN phosphatase. J Biol Chem 2003;278:26929-37
37. Yeon JE, Califano S, Xu J. Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology 2003;38:703-14
38. Ausubel F, Brent R, Kingston R, et al. Current Protocols in Molecular Biology. New York, NY: Wiley Interscience, 2000
39. Lester-Coll N, Rivera EJ, Soscia SJ. Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006;9:13-33
40. Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 2005;8:247-68
41. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005;7:63-80
42. de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 2006;9:167-81
43. de la Monte SM, Sohn YK, Etienne D, et al. Role of aberrant nitric oxide synthase-3 expression in cerebrovascular degeneration and vascular-mediated injury in Alzheimer's disease. Ann NY Acad Sci 2000;903:61-71
44. Mir LM, Bureau MF, Rangara R, et al. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. CR Acad Sci III 1998;321:893-99
45. Maruyama H, Ataka K, Gejyo F, et al. Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats. Gene Ther 2001;8:461-6
46. Draghia-Akli R, Ellis KM, Hill LA, et al. High-efficiency growth hormone-releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs. FASEB J 2003;17:526-28
47. Nagy ZS, Esiri MM. Apoptosis-related protein expression in the hippocampus in Alzheimer's disease. Neurobiol Aging 1997;18:565-71
48. Anderson AJ, Su JH, Cotman CW. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 1996;16:1710-19
49. Jacotot E, Costantini P, Laboureau E, et al. Mitochondrial membrane permeabilization during the apoptotic process. Ann NY Acad Sci 1999;887:18-30
50. Bosca L, Hortelano S. Mechanisms of nitric oxide-dependent apoptosis: Involvement of mitochondrial mediators. Cell Signal 1999;11239-44
51. de la Monte SM, Neely TR, Cannon J, et al. Oxidative stress and hypoxia-like injury cause Alzheimer-type molecular abnormalities in central nervous system neurons. Cell Mol Life Sci 2000;57:1471-81
52. Lemasters JJ, Qian T, He L, et al. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid Redox Signal 2002;4:769-81
53. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997;94:514-19
54. Budd SL, Tenneti L, Lishnak T, et al. Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proc Natl Acad Sci USA 2000;97:6161-66
55. Korsmeyer SJ, Shutter JR, Veis DJ, et al. Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993;4:327-32
56. Crawford DR, Lauzon RJ, Wang Y, et al. 16S mitochondrial ribosomal RNA degradation is associated with apoptosis. Free Radic Biol Med 1997;22:1295-1300
57. Jackson GR, Wiedau-Pazos M, Sang TK, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002;34:509-19
58. Veeranna GJ, Shetty KT, Takahashi M, et al. Cdk5 and MAPK are associated with complexes of cytoskeletal proteins in rat brain. Brain Res Mol Brain Res 2000;76:229-36
59. Crowder RJ, Freeman RS. Glycogen synthase kinase-3 β activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 2000;275:34266-71
60. Hetman M, Cavanaugh JE, Kimelman D, et al. Role of glycogen synthase kinase-3β in neuronal apoptosis induced by trophic withdrawal. J Neurosci 2000;20:2567-74
61. de la Monte SM. Molecular abnormalities of the brain in Down syndrome: Relevance to Alzheimer's neurodegeneration. J Neural Transm 1999;57(Suppl):1-19
62. Tandon A, Frasier P. The presenilins. Genome Biol 2002;3:reviews3014
63. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the β-amyloid protein in Alzheimer's disease. Neuromolecular Med 2002;1:1-31
64. Rogaeva E. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromolecular Med 2002;2:1-10
65. Badan I, Platt D, Kessler C, et al. Temporal dynamics of degenerative and regenerative events associated with cerebral ischemia in aged rats. Gerontology 2003;49:356-65
66. Chen GJ, Xu J, Lahousse SA, et al. Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: Potential strategies for neuroprotection. J Alzheimers Dis 2003;5:209-28
67. Mattson MP, Pedersen WA, Duan W, et al. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann NY Acad Sci 1999;893:154-75
68. Cassarino DS, Bennett JP Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: Mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev 1999;29:1-25
69. Torok NJ, Higuchi H, Bronk S, et al. Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. Cancer Res 2002;62:1648-53
70. Almeida A, Bolanos JP. A transient inhibition of mitochondrial ATP synthesis by nitric oxide synthase activation triggered apoptosis in primary cortical neurons. J Neurochem 2001;77:676-90
71. Ghafourifar P, Bringold U, Klein SD, et al. Mitochondrial nitric oxide synthase, oxidative stress and apoptosis. Biol Signals Recept 2001;10:57-65
72. Horvath TL, Diano S, Barnstable C. Mitochondrial uncoupling protein 2 in the central nervous system: Neuromodulator and neuroprotector. Biochem Pharmacol 2003;65:1917-21
73. Mattson MP, Liu D. Mitochondrial potassium channels and uncoupling proteins in synaptic plasticity and neuronal cell death. Biochem Biophys Res Commun 2003;304:539-49
74. Bishop-Bailey D, Wray J. Peroxisome proliferator-activated receptors: A critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat 2003;71:1-22
75. Gilde AJ, Van Bilsen M. Peroxisome proliferator-activated receptors (PPARS): Regulators of gene expression in heart and skeletal muscle. Acta Physiol Scand 2003;178:425-34
76. Lee CH, Olson P, Evans RM. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-7
77. Sayre LM, Zelasko DA, Harris PL, et al. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997;68:2092-97
78. Montine KS, Kim PJ, Olson SJ, et al. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 1997;56:866-71
79. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol 1999;9:133-46
80. de la Monte SM, Wands JR. Alzheimer-associated neuronal thread protein mediated cell death is linked to impaired insulin signaling. J Alzheimers Dis 2003;6:231-42
81. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: Implications for treatment. CNS Drugs 2003;17:27-45
82. Deplanque D, Gele P, Petrault O, et al. Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003;23:6264-71
83. Sivarajah A, Chatterjee PK, Patel NS, et al. Agonists of peroxisome-proliferator activated receptor-γ reduce renal ischemia/reperfusion injury. Am J Nephrol 2003;23:267-76
84. de la Monte SM, Tong M, Lester-Coll N, et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. J Alzheimers Dis 2006;10:89-109